Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia
We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl an...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2013, Vol.52(22), pp.2567-2571 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2571 |
|---|---|
| container_issue | 22 |
| container_start_page | 2567 |
| container_title | Internal Medicine |
| container_volume | 52 |
| creator | Nagao, Takayo Takahashi, Naoto Kameoka, Yoshihiro Noguchi, Shinsuke Shinohara, Yoshinori Ohyagi, Hideaki Kume, Masaaki Sawada, Kenichi |
| description | We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy. |
| doi_str_mv | 10.2169/internalmedicine.52.0392 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534840071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534840071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c617t-6a496fe6e519c5cf7fcdaaab208478f2e0fd0cf431957e0d00db945f35c2a2b13</originalsourceid><addsrcrecordid>eNqNkU2P0zAQhi0EYsvCX0A-ckkZfyXxEZWPXaloOSxny3HGWy-JXex0Rf89qVpyQBy4zIw0z_uONC8hlMGas1q_D3HCHO0wYh9ciLhWfA1C82dkxYTUVcOFek5WoFlb8blckVelPAKIttH8JbnikktodLsi8aMtdgoxdFXGsk-xhCekm11OMTi6PY77XXLH6TTj4QeOwdIQqaXfZhHGid5ntBP21KdMNwl_hTKbPSwGX484pNAv4tfkhbdDwTeXfk2-f_50v7mptndfbjcftpWrWTNVtZW69lijYtop5xvvemttx6GVTes5gu_BeSmYVg1CD9B3WiovlOOWd0xck3dn331OPw9YJjOG4nAYbMR0KIYpIVsJ0PwHKpVWNQgFM9qeUZdTKRm92ecw2nw0DMwpGPN3MEZxcwpmlr69XDl083IR_kliBu7OwGOZ7AMugM3z8wf8pzPnp3o5sZBuZ7PBKH4DuXWt-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1459560350</pqid></control><display><type>article</type><title>Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Nagao, Takayo ; Takahashi, Naoto ; Kameoka, Yoshihiro ; Noguchi, Shinsuke ; Shinohara, Yoshinori ; Ohyagi, Hideaki ; Kume, Masaaki ; Sawada, Kenichi</creator><creatorcontrib>Nagao, Takayo ; Takahashi, Naoto ; Kameoka, Yoshihiro ; Noguchi, Shinsuke ; Shinohara, Yoshinori ; Ohyagi, Hideaki ; Kume, Masaaki ; Sawada, Kenichi</creatorcontrib><description>We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.52.0392</identifier><identifier>PMID: 24240798</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Chromosome Deletion ; Chromosome Disorders - genetics ; Chromosomes, Human, Pair 13 - genetics ; chronic lymphoid leukemia ; chronic myeloid leukemia ; Dasatinib ; Female ; fluorescent in situ hybridization ; Genes, abl ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; multi-tyrosine kinase inhibitor ; Neoplasms, Multiple Primary - drug therapy ; Neoplasms, Multiple Primary - genetics ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines - therapeutic use ; Thiazoles - therapeutic use</subject><ispartof>Internal Medicine, 2013, Vol.52(22), pp.2567-2571</ispartof><rights>2013 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c617t-6a496fe6e519c5cf7fcdaaab208478f2e0fd0cf431957e0d00db945f35c2a2b13</citedby><cites>FETCH-LOGICAL-c617t-6a496fe6e519c5cf7fcdaaab208478f2e0fd0cf431957e0d00db945f35c2a2b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24240798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagao, Takayo</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Kameoka, Yoshihiro</creatorcontrib><creatorcontrib>Noguchi, Shinsuke</creatorcontrib><creatorcontrib>Shinohara, Yoshinori</creatorcontrib><creatorcontrib>Ohyagi, Hideaki</creatorcontrib><creatorcontrib>Kume, Masaaki</creatorcontrib><creatorcontrib>Sawada, Kenichi</creatorcontrib><title>Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy.</description><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Chromosome Deletion</subject><subject>Chromosome Disorders - genetics</subject><subject>Chromosomes, Human, Pair 13 - genetics</subject><subject>chronic lymphoid leukemia</subject><subject>chronic myeloid leukemia</subject><subject>Dasatinib</subject><subject>Female</subject><subject>fluorescent in situ hybridization</subject><subject>Genes, abl</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>multi-tyrosine kinase inhibitor</subject><subject>Neoplasms, Multiple Primary - drug therapy</subject><subject>Neoplasms, Multiple Primary - genetics</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Thiazoles - therapeutic use</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2P0zAQhi0EYsvCX0A-ckkZfyXxEZWPXaloOSxny3HGWy-JXex0Rf89qVpyQBy4zIw0z_uONC8hlMGas1q_D3HCHO0wYh9ciLhWfA1C82dkxYTUVcOFek5WoFlb8blckVelPAKIttH8JbnikktodLsi8aMtdgoxdFXGsk-xhCekm11OMTi6PY77XXLH6TTj4QeOwdIQqaXfZhHGid5ntBP21KdMNwl_hTKbPSwGX484pNAv4tfkhbdDwTeXfk2-f_50v7mptndfbjcftpWrWTNVtZW69lijYtop5xvvemttx6GVTes5gu_BeSmYVg1CD9B3WiovlOOWd0xck3dn331OPw9YJjOG4nAYbMR0KIYpIVsJ0PwHKpVWNQgFM9qeUZdTKRm92ecw2nw0DMwpGPN3MEZxcwpmlr69XDl083IR_kliBu7OwGOZ7AMugM3z8wf8pzPnp3o5sZBuZ7PBKH4DuXWt-A</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Nagao, Takayo</creator><creator>Takahashi, Naoto</creator><creator>Kameoka, Yoshihiro</creator><creator>Noguchi, Shinsuke</creator><creator>Shinohara, Yoshinori</creator><creator>Ohyagi, Hideaki</creator><creator>Kume, Masaaki</creator><creator>Sawada, Kenichi</creator><general>The Japanese Society of Internal Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20130101</creationdate><title>Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia</title><author>Nagao, Takayo ; Takahashi, Naoto ; Kameoka, Yoshihiro ; Noguchi, Shinsuke ; Shinohara, Yoshinori ; Ohyagi, Hideaki ; Kume, Masaaki ; Sawada, Kenichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c617t-6a496fe6e519c5cf7fcdaaab208478f2e0fd0cf431957e0d00db945f35c2a2b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Chromosome Deletion</topic><topic>Chromosome Disorders - genetics</topic><topic>Chromosomes, Human, Pair 13 - genetics</topic><topic>chronic lymphoid leukemia</topic><topic>chronic myeloid leukemia</topic><topic>Dasatinib</topic><topic>Female</topic><topic>fluorescent in situ hybridization</topic><topic>Genes, abl</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>multi-tyrosine kinase inhibitor</topic><topic>Neoplasms, Multiple Primary - drug therapy</topic><topic>Neoplasms, Multiple Primary - genetics</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Thiazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagao, Takayo</creatorcontrib><creatorcontrib>Takahashi, Naoto</creatorcontrib><creatorcontrib>Kameoka, Yoshihiro</creatorcontrib><creatorcontrib>Noguchi, Shinsuke</creatorcontrib><creatorcontrib>Shinohara, Yoshinori</creatorcontrib><creatorcontrib>Ohyagi, Hideaki</creatorcontrib><creatorcontrib>Kume, Masaaki</creatorcontrib><creatorcontrib>Sawada, Kenichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagao, Takayo</au><au>Takahashi, Naoto</au><au>Kameoka, Yoshihiro</au><au>Noguchi, Shinsuke</au><au>Shinohara, Yoshinori</au><au>Ohyagi, Hideaki</au><au>Kume, Masaaki</au><au>Sawada, Kenichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>52</volume><issue>22</issue><spage>2567</spage><epage>2571</epage><pages>2567-2571</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>24240798</pmid><doi>10.2169/internalmedicine.52.0392</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2013, Vol.52(22), pp.2567-2571 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1534840071 |
| source | J-STAGE Free; MEDLINE |
| subjects | Aged, 80 and over Antineoplastic Agents - therapeutic use Chromosome Deletion Chromosome Disorders - genetics Chromosomes, Human, Pair 13 - genetics chronic lymphoid leukemia chronic myeloid leukemia Dasatinib Female fluorescent in situ hybridization Genes, abl Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics multi-tyrosine kinase inhibitor Neoplasms, Multiple Primary - drug therapy Neoplasms, Multiple Primary - genetics Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Thiazoles - therapeutic use |
| title | Dasatinib-responsive Chronic Lymphocytic Leukemia in a Patient Treated for Coexisting Chronic Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A06%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dasatinib-responsive%20Chronic%20Lymphocytic%20Leukemia%20in%20a%20Patient%20Treated%20for%20Coexisting%20Chronic%20Myeloid%20Leukemia&rft.jtitle=Internal%20Medicine&rft.au=Nagao,%20Takayo&rft.date=2013-01-01&rft.volume=52&rft.issue=22&rft.spage=2567&rft.epage=2571&rft.pages=2567-2571&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.52.0392&rft_dat=%3Cproquest_cross%3E1534840071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1459560350&rft_id=info:pmid/24240798&rfr_iscdi=true |